Anti-PD-1 Therapy Boosts Survival in High-Risk HCC Patients

Postoperative anti-PD-1 therapy significantly enhances overall survival and recurrence-free survival in hepatocellular carcinoma (HCC) patients, particularly those with vessels encapsulating tumor clusters (VETC), a marker of aggressive disease. Among 388 patients studied, those receiving the therapy showed improved outcomes compared to untreated counterparts, while VETC status emerged as a crucial prognostic biomarker. This study underscores the importance of tailoring immunotherapy based on disease aggressiveness.